Abbott Laboratories: Q1 2020 Form 10-Q Summary
Business context and reporting period
Abbott Laboratories reported unaudited results for the three months ended March 31, 2020. The company operates across Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices. The quarter was materially affected by the COVID-19 pandemic, which reduced routine diagnostic testing and elective cardiovascular and neuromodulation procedures while increasing demand for certain nutrition and COVID-19 diagnostic products.
Key financial metrics
| Metric | Q1 2020 | Q1 2019 | Change |
|---|---|---|---|
| Net sales | $7,726 million | $7,535 million | 2.5% |
| Operating earnings | $758 million | $739 million | 2.6% |
| Earnings from continuing operations | $544 million | $672 million | (19.0%) |
| Net earnings | $564 million | $672 million | (16.1%) |
| Diluted earnings per share | $0.31 | $0.38 | (18.4%) |
| Net cash from operating activities | $715 million | $712 million | 0.4% |
- Gross margin was 50.3%, compared with 51.6% in the prior-year quarter. The decline primarily reflected higher intangible amortization and unfavorable foreign exchange.
- Operating margin was approximately 9.8%, compared with approximately 9.8% in Q1 2019. Net margin was approximately 7.3%, compared with approximately 8.9%.
- Cash and cash equivalents were $3.377 billion at March 31, 2020, down from $3.860 billion at December 31, 2019. Cash and short-term investments totaled approximately $3.7 billion.
- Total debt was approximately $18.1 billion, consisting of $1.264 billion of current long-term debt, $204 million of short-term borrowings, and $16.804 billion of long-term debt.
- Abbott had $5.0 billion of available credit lines expiring in 2023 and stated that it expected to maintain an investment-grade rating. Long-term debt was rated A- by Standard & Poor’s and A3 by Moody’s.
- Capital expenditures were $360 million. Investing cash flow was $(393) million and financing cash flow was $(735) million, including $638 million of dividends paid and $236 million of share purchases.
- Working capital was approximately $4.7 billion at quarter-end, compared with $4.8 billion at December 31, 2019.
Material changes versus the prior comparable period
- Sales increased 4.3% excluding foreign exchange, while the stronger U.S. dollar reduced reported sales growth by 1.8 percentage points.
- Established Pharmaceutical Products sales rose 5.2% reported and 9.3% excluding foreign exchange. Nutritional Products sales rose 6.3% reported and 7.3% excluding foreign exchange.
- Diagnostic Products sales declined 0.8% reported but increased 0.7% excluding foreign exchange. Core Laboratory sales declined 4.9% excluding foreign exchange because of lower routine testing volumes, partly offset by 30.3% growth in Molecular Diagnostics.
- Medical Devices sales increased 1.4% reported and 2.9% excluding foreign exchange. Diabetes Care sales increased 35.6% excluding foreign exchange, including FreeStyle Libre sales of $604 million, up 62.5%.
- Research and development expense declined $94 million, or 14.1%, principally because Q1 2019 included a $102 million immediate charge for an acquired R&D asset related to Cephea Valve Technologies.
- Interest expense, net declined $27 million due to lower financing costs and prior debt repayment. Other income declined because Abbott recorded an approximately $50 million equity-investment impairment.
- Net earnings included $20 million of discontinued-operations tax benefits related to the resolution of prior tax positions. Q1 2019 included a $78 million reduction to the transition tax under the Tax Cuts and Jobs Act.
- Comprehensive income was $(357) million, compared with $788 million in Q1 2019, primarily because of a $1.144 billion foreign-currency translation loss.
Guidance, outlook, risks, contingencies, and unusual items
- The filing does not provide a clear quantitative earnings or revenue outlook. Management stated that the duration and impact of COVID-19 could not be predicted and could materially affect operations, financial condition, and results.
- Abbott launched COVID-19 molecular tests on its ID NOW and m2000 platforms during March and launched a laboratory serology test in April. Management expects demand for cardiovascular and neuromodulation products to increase when healthcare services normalize.
- COVID-19 risks include reduced elective procedures and routine testing, supply-chain and manufacturing disruption, difficulty serving customers, economic weakness, and foreign-exchange and capital-market volatility.
- Restructuring charges totaled $32 million in Q1 2020, with $126 million of related restructuring accruals remaining at March 31, 2020 across the disclosed plans.
- Legal and environmental proceedings had an estimated possible loss range of approximately $90 million to $125 million and an accrued balance of approximately $110 million. Management did not expect the ultimate disposition to materially affect financial position, cash flows, or results.
- Abbott believed gross unrecognized tax benefits could decrease by approximately $230 million to $520 million within the next twelve months as tax matters are resolved.
- The company adopted the current expected credit loss standard on January 1, 2020; the cumulative adjustment was not significant. Adoption of the new income-tax standard in the first quarter of 2021 is not expected to have a material effect.
- Disclosure controls were deemed effective, and the filing reported no material changes in internal control over financial reporting.
Important facts for investors to verify
- Whether COVID-19-related declines in elective procedures and routine testing persist or are offset by COVID-19 diagnostic-test demand.
- The sustainability of growth in FreeStyle Libre, Molecular Diagnostics, nutrition, and Established Pharmaceuticals.
- Cash conversion, inventory growth, pension contributions, capital expenditures, dividends, and debt repayment capacity.
- Future intangible-amortization expense, restructuring costs, investment impairments, and foreign-currency effects on margins.
- Resolution of tax positions, legal proceedings, environmental matters, and the remaining debt-redemption authorization.
- The filing’s stated COVID-19 uncertainty and the absence of clear quantitative guidance for the remainder of 2020.